"U.S. Cannabinoids Market Growth & Trends The U.S. cannabinoids market size is expected to reach USD 16.4 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 20.4% from 2020 to 2027. Growing consumer awareness regarding various health benefits offered by cannabinoids and growing number of new entrants in the market, leading to expansion in product availability are driving the market. Rising adoption and acceptance of cannabinoids based treatment among consumers over antibiotics treatment is likely to fuel the growth of the market. Furthermore, changing buyer perception and attitude toward these products is further bolstering revenue growth. Based on product, the cannabidiol (CBD) segment dominated the market in 2019. This growth is attributed to various factors such as a rise in the consumption of CBD-based products in weight management, health and wellness, sports nutrition, and other fields. In addition, companies are constantly trying to diversify their products into different forms to cater to a larger consumer pool to improve product penetration into newer consumer segments and to increase brand visibility. Companies are undertaking various strategic initiatives to expand their presence in the market. For instance, in March 2020, Reakiro, a European CBD company, launched its CBD products-including capsules, oils, and soft gels-in the U.S., after looking at the significant demand for CBD-infused dietary supplements and products in the country. On the other hand, CBDa products are anticipated to witness the fastest growth over the forecast period owing to potential health benefits offered by these products as well as increasing efficiency in managing health conditions. Moreover, the health benefits of cannabinoids and affirmative research efforts that can demonstrate the benefits of these products in conditions such as analgesia, sleep disorders, and mental disorders have fueled the market in the country. For instance, a study of 72 adults suffering from anxiety and sleep disorders in the U.S. was carried out by The Permanente Journal in 2019. After one month of undergoing treatment with 25 mg CBD capsules, around 66.0% of patients indicated lesser trouble with sleeping. The rise in the number of manufacturers offering bulk as well and finished cannabinoid products is boosting market growth in the country. The ongoing COVID-19 pandemic is further impacting the overall cannabis industry in the region. As per Orange County Register, on March 17, 2020, some dispensaries such as Bud and Bloom witnessed an overall increase in weekly sales by over 30.0%. U.S. Cannabinoids Market Report Highlights • The size is anticipated to be valued at USD 16.4 billion by 2027, owing to increasing legalization of these products • CBD products dominated the market in 2019, owing to affirmative legal scenarios, ease of accessibility, and increase in awareness about CBD • CBDa products are anticipated to witness the fastest growth over the forecast period owing to potential health benefits and higher efficiency in managing health conditions"
"Table of Contents Chapter 1 Methodology and Scope 1.1 Research Methodology 1.1.1 Information Procurement 1.2 Information or Data Analysis 1.3 Market Formulation & Validation 1.3.1 CAGR Calculation 1.4 Region Based Segment Share Calculation 1.5 List of Secondary Sources Chapter 2 Executive Summary 2.1 Market Summary Chapter 3 U.S. Cannabinoids Market Variables, Trends & Scope 3.1 Market Segmentation 3.2 Penetration & Growth Prospects Mapping 3.3 U.S. Cannabinoids Market Dynamics 3.3.1 Market Driver Analysis 126.96.36.199 Growing number of new entrants in the market leading to expansion in product availability 188.8.131.52 Increasing number of consumers opting for isolated cannabinoid products 184.108.40.206 Growing number of clinical studies on the use of cannabinoids for specific applications 220.127.116.11 Rising awareness pertaining to cannabinoid products and their use in health and wellness 3.3.2 Market Restraint Analysis 18.104.22.168 High price of cannabinoids-based products 22.214.171.124 Expensive extraction processes for cannabinoids 126.96.36.199 Absence of definite regulatory framework for minor cannabinoids 3.4 U.S. Cannabinoids Market Analysis Tools 3.4.1 U.S. Cannabinoids Market - PESTLE Analysis 3.4.2 U.S. Cannabinoids Market - Porter’s Analysis 3.5 Supply Chain Analysis 3.5.1 Supply Chain Analysis - CBD Consumer Health Product 188.8.131.52 Profit Margin Estimation 3.6 Opportunity Analysis 3.7 Regulatory Scenario 3.8 Product Adoption Pattern Analysis 3.8.1 Cannabidiol (CBD) 3.8.2 Tetrahydrocannabinol (THC) 3.8.3 Cannabinol (CBN) 3.8.4 Cannabidiolic Acid (CBDA) 3.8.5 Others 184.108.40.206 Cannabigerol (CBG) 220.127.116.11 Cannabichromene (CBC) 3.9 Pricing Analysis, Product Type, 2019-2027 Chapter 4 U.S Cannabinoids Market: Product Estimates & Trend Analysis 4.1 U.S. Cannabinoids Market: Product Movement Analysis 4.2 Market Revenue Size and Forecasts and Trend Analysis 2016-2027 for the following product types: 4.2.1 Cannabidiol (CBD) 18.104.22.168 CBD Market Estimates and Forecasts, 2016 - 2027 (USD Million) 4.2.2 Tetrahydrocannabinol (THC) 22.214.171.124 THC Market Estimates and Forecasts, 2016 - 2027 (USD Million) 4.2.3 Cannabinol (CBN) 126.96.36.199 CBN Market Estimates and Forecasts, 2016 - 2027 (USD Million) 4.2.4 Cannabidiolic Acid (CBDA) 188.8.131.52 CBDa Market Estimates and Forecasts, 2016 - 2027 (USD Million) 4.2.5 Other Cannabinoids (CBG AND CBC) 184.108.40.206 Other Cannabinoids (CBG and CBC) Market Estimates and Forecasts, 2016 - 2027 (USD Million) Chapter 5 Competitive Landscape 5.1 Company Profiles 5.1.1 Mile High Labs International 220.127.116.11 Company overview 18.104.22.168 Financial performance 22.214.171.124 Product benchmarking 126.96.36.199 Strategic initiatives 5.1.2 Global Cannabinoids 188.8.131.52 Company overview 184.108.40.206 Financial performance 220.127.116.11 Product benchmarking 18.104.22.168 Strategic initiatives 5.1.3 Gencanna 22.214.171.124 Company overview 126.96.36.199 Financial performance 188.8.131.52 Product benchmarking 184.108.40.206 Strategic initiatives 5.1.4 CBD Inc Group 220.127.116.11 Company overview 18.104.22.168 Product benchmarking 5.1.5 SPARKCBD 22.214.171.124 Company overview 126.96.36.199 Product benchmarking 5.1.6 Rhizo Sciences 188.8.131.52 Company overview 184.108.40.206 Financial performance 220.127.116.11 Product benchmarking 18.104.22.168 Strategic initiatives 5.1.7 Maricann, Inc. 22.214.171.124 Company overview 126.96.36.199 Product benchmarking "
"List of Tables Table 1 Partial list of secondary sources Table 2 Average Selling price of cannabinoids in the U.S., by product, 2019 - 2027 (USD/mg)" "List of Figures Fig. 1 Market research process Fig. 2 Information procurement Fig. 3 Primary research pattern Fig. 4 Market research approaches Fig. 5 Value chain based sizing & forecasting Fig. 6 QFD modelling for market share assessment Fig. 7 Market formulation & validation Fig. 8 U.S. Cannabinoids market snapshot, 2019 (USD Million) Fig. 9 U.S. Cannabinoids market dynamics Fig. 10 U.S.Cannabinoids market segmentation Fig. 11 Penetration & growth prospects mapping for U.S. Cannabinoids market Fig. 12 U.S. Cannabinoids market driver impact Fig. 13 U.S. Cannabinoids market restraints impact Fig. 14 U.S. Cannabinoids market - PESTLE analysis Fig. 15 U.S. Cannabinoids market - Porter’s Analysis Fig. 16 Supply chain network of CBD isolates and full spectrum extracts Fig. 17 Supply chain network of CBD isolates and full spectrum distillates Fig. 18 Methods of estimation Fig. 19 Opportunity analysis (USD Million) Fig. 20 U.S. Cannabinoids market, Product outlook: Key takeaways Fig. 21 U.S. Cannabinoids market: Product movement analysis (2019 & 2027) (USD Million) Fig. 22 CBD market estimates and forecasts, 2016 - 2027 (USD Million) Fig. 23 THC market estimates and forecasts, 2016 - 2027 (USD Million) Fig. 24 CBN market estimates and forecasts, 2016 - 2027 (USD Million) Fig. 25 CBDa market estimates and forecasts, 2016 - 2027 (USD Million) Fig. 26 Other cannabinoids market estimates and forecasts, 2016 - 2027 (USD Million)"
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.